Compare WAFU & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WAFU | PMCB |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.6M |
| IPO Year | 2019 | N/A |
| Metric | WAFU | PMCB |
|---|---|---|
| Price | $1.66 | $0.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.1K | ★ 3.0M |
| Earning Date | 01-01-0001 | 12-15-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $6,186,645.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $119.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.22 | $0.63 |
| 52 Week High | $7.49 | $1.90 |
| Indicator | WAFU | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 46.60 | 42.70 |
| Support Level | $1.62 | $0.63 |
| Resistance Level | $1.76 | $1.20 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 23.94 | 19.81 |
Wah Fu Education Group Ltd is involved in providing online exam preparation services and related technology solutions, and also produces online training course materials in China. It develops online educational materials that are offered through the cloud and that can be used for a wide range of purposes, such as standard examination preparation, professional training, and interactive programs for educational purposes other than exam preparation. Its segments are Online Education Services and Technological Development and Operation Service. The company generates maximum revenue from the Online Education Services segment.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.